Skip to main content

Table 1 Neutralization profile of patient ITM4 in a primary virus/PBMC assay (left) and a pseudovirus/TZM-bl assay (right)

From: Evolution of antibody landscape and viral envelope escape in an HIV-1 CRF02_AG infected patient with 4E10-like antibodies

  PBMC/Primary Virus Assay Plasma Sample ITM4_05 Pseudovirus/TZM bl Assay Plasma Sample ITM4_07
Subtype Virus % Neutralizationa Pseudovirus ID50b
A VI 191 66 PV 92RW009 222
  92UG037 100 PV PIC 32281 54
  VI 820 99   
  VI 1031 100   
B 89.6 0 PV SF162 322
  93US076 69 PV JRFL 88
  93US077 97 PV AC10 62
  93US143 100 PV CAAN 33
C VI 829 80 PV VI 829 180
  VI 882 99 PV VI 882 316
  VI 1358 99 PV VI 1358 208
  VI 1144 100 PV 92BR025 155
    PV Du174 333
D VI 656 97 PV UG024 >640
  VI 693 100   
  VI 824 91   
  VI 865 93   
CRF01 VI 1249 98 PV CM244 93
  CA 10 97   
  VI 1888 96   
  92TH022 99   
CRF02 VI 1090 94 PV VI 1090 221
  CA18 88 PV CA18 63
  VI 2680 99   
  VI 1380 98   
  VI 2727 93   
  1. a % neutralization obtained with 1:20 plasma dilution, ≥80% reduction in virus titer is indicated in bold.
  2. b Plasma dilution causing 50% reduction of relative light units compared to the virus control, ID50 ≥50 is indicated in bold.